CB-103 Plus NSAI In Luminal Advanced Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Multicenter, single-arm, open label, phase II clinical trial with safety run-in to evaluate
the safety, tolerability, pharmacokinetics and efficacy of CB-103 in combination with a
non-steroidal aromatase inhibitor (NSAI), anastrozole or letrozole, in Hormone
Receptor-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced
breast cancer patients who have achieved clinical benefit during prior NSAI-based treatment.